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Background and Purpose.Anxiety affects 25% of stroke survivors.There are no effective treatments. Poststroke depression, prestroke
anxiety and depression, locus of control, coping, confidence, fatigue, and sleep are factors that may be associated with poststroke
anxiety and can potentially be targeted by therapy. We systematically reviewed the literature and performed a meta-analysis to
identify associations with these factors.Methods. We searched electronic databases from January 2014 to July 2015 to complement
a literature search performed from inception to May 2014. Study quality was assessed using an internationally endorsed checklist.
We used odds ratios (ORs) to estimate the strength of associations and random-effects modelling to calculate summary effect
sizes. Results. There were 24 studies recruiting 15448 patients. Quality of reporting was satisfactory. 13 studies with 2408 patients
reported associations between poststroke anxiety and poststroke depression (OR = 4.66, 95% confidence interval: 2.23, 9.74). One
study reported association with prestroke anxiety, three with prestroke depression, one with fatigue, and two with sleep. No studies
reported on locus of control, coping, or confidence. Conclusion. Poststroke anxiety was associated with depression but there are
limited data on other modifiable associations. Further research is needed to identify potential targets for treatment.
1. Introduction
A clinically significant mental health disorder occurs in
greater than one-third of poststroke patients and may be
associated with increased morbidity and mortality [1]. The
most common disorders after stroke are depression and anx-
iety [2]. Worldwide, anxiety disorders are the most prevalent
group of mental health disorders, with an estimated lifetime
prevalence of approximately 11% [3]. Anxiety following a
stroke or transient ischaemic attack (TIA) occurs in about
24% of patients [4] and is a distressing problem associated
with poorer health related quality of life [5]. Despite its
prevalence, poststroke anxiety (PSA) is an understudied area
in comparison to other psychological poststroke disorders
such as depression [4].There are no studies on the prevention
of PSA [2] and very few randomised trials of intervention to
treat it [6]. This may partly reflect a lack of data reporting
its risk factors and associations. In order to develop effective
therapies for PSA, we need to better understand its associa-
tions which could provide targets for treatment.
Although there has been a previous systematic review on
associations of PSA [7], a meta-analysis of the strength of
associations was not performed. Furthermore the searches
were performed in May 2014 and further studies have been
published since. In our systematic review we wish to focus
on potentially modifiable factors that could be targeted by
therapy.We will determine the association with the following
factors of interest: poststroke depression (PSD), prestroke
anxiety and depression, locus of control, coping, confidence,
fatigue, and sleep, and we will perform a meta-analysis to
estimate the strength of associations.
2. Methods
Our review updates and complements an earlier systematic
review on the associations of PSA by Menlove et al. which
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reported searches from inception to May 2014. Their search
strategy can be found in their primary publication [7].
We applied our search strategy from Jan 2014 to 19th
July 2015 using the databasesMEDLINE, EMBASE, CINAHL
PLUS, AMED, PsychINFO, and ProQuest dissertation.There
was an overlap in the search period (four months) with
Menlove’s review to ensure studies that were in print were
not missed. We used search terms synonymous with stroke
and anxiety obtained from a Cochrane review of inter-
ventions for PSA [6]. This review’s search strategy can be
found in the Supplementary Material available online at
https://doi.org/10.1155/2017/2124743.
One author (FW) screened all titles and excluded the
obviously irrelevant. The remaining citations were exported
to EndNote and two authors (FW and HYC) independently
screened the abstracts to decide which to obtain as a full
text. The two authors independently read all full texts and
decided which studies fulfilled the eligibility criteria. Any
discrepancies were dealt with through discussion.
Our inclusion criteria were as follows: (1) studies on
stroke patients including ischaemic, haemorrhagic, or unspe-
cified stroke subtype; (2) incidence studies, cohort studies,
cross-sectional studies, case control studies, or case series
that made use of consecutive patient recruitment within
clearly defined geographical and time-limited boundaries; (3)
assessed anxiety using a validated anxiety scale or clinical
diagnostic criteria in a psychiatric interview; (4) used regres-
sion analyses; and (5) reported in English.
Studies were excluded if they (1) had mixed populations
(unless separate results for stroke patients were reported);
(2) were limited to select patient characteristics (such as age,
gender, and lesion side); (3) used retrospective recruitment or
reporting of mood; (4) did not measure anxiety specifically;
(5) contained insufficient data for reporting of associations;
(6) included participants <18 years old; (7) were case reports
or included <10 participants; (8) were intervention studies;
or (9) included >25% of participants with TIA rather than
stroke.
Two authors (FW and HYC) independently extracted
data onto electronic tables. Variables included demographics,
time points, and measures for assessing anxiety, proportion
who had PSA, statistical methods for analysing associa-
tions, and factors including PSD, prestroke anxiety, prestroke
depression, locus of control, coping, confidence, fatigue, and
sleep disturbance.
The quality of each study was assessed independently
by two authors (FW and HYC) using The Strengthening
the Reporting of Observational studies in Epidemiology
(STROBE) checklist [8] consisting of 22 items required for
good reporting of observational studies.
We included studies [9–11] that solely included patients
with posttraumatic stress disorder (PTSD) following a stroke
as it is classified as an anxiety disorder under the Diagnostic
and Statistical Manual of Mental Disorders IV (DSM-IV)
criteria and its older versions. While the latest DSM-V no
longer includes PTSD under the classification of anxiety
disorders [12] all of the included studies usedmeasures based
on the DSM-IV-TR or earlier versions.
The authors conducted this systematic review within the
Centre for Cognitive Ageing and Cognitive Epidemiology
(CCACE) which is funded by the Medical Research Coun-
cil (MRC) and the Biotechnology and Biological Sciences
Research Council (BBSRC).
2.1. Statistical Analysis. In order to carry out a meta-analysis
of the association between PSA and the factors of interest, we
calculated odds ratios (ORs) and 95% confidence intervals
(95% CI) from raw data where possible. For meta-analysis,
if raw data were not available, ORs and 95% CIs reported
in the studies were used. If only correlation coefficients were
available, these were converted into ORs using conventional
methods [13]. We used funnel plotting to assess publication
bias [14].
Random-effects modelling was used to determine the
summary estimate of OR [15]. The Cochran 𝑄 statistic was
used to assess heterogeneity between studies, where a 𝑝
value of < 0.05 indicates significant heterogeneity [16]. We
partitioned heterogeneity between studies reporting adjusted
ORs and those reporting unadjusted ORs [16].
3. Results
Our searches identified 2061 studies. We obtained 100 full
texts and six [11, 17–21] fulfilled our eligibility criteria in
addition to the 18 studies [9, 10, 22–37] froma previous review
[7] which had the same inclusion criteria applied. Figure 1
shows reasons for exclusion.We included a total of 24 studies.
The 24 studies recruited a total of 15448 participants,
with a mean age ranging from 51.7 to 75.2 years (though
four studies did not report mean age [20, 22, 25, 34]). The
proportion of females ranged from 20.8% to 59.3% with one
study not reporting this data [22]. Six studies had participants
with ischaemic stroke [25, 26, 29, 31, 32, 36], nine had both
ischaemic and haemorrhagic stroke [18, 19, 21, 23, 27, 28,
30, 35, 37], and nine did not specify the type of stroke [9–
11, 17, 20, 22, 24, 33, 34]. 13 studies recruited participants from
hospital [9, 10, 21, 25–31, 34–36], four from rehabilitation
centres [18, 23, 33, 37], three from the community (including
outpatient clinics) [11, 19, 20], and four from the population
(such as stroke registers) [17, 22, 24, 32]. Studies assessed
anxiety at varying time points after stroke, ranging from 3
days to yearly for 20 years.
To assess the presence of anxiety, 13 studies used the
Hospital Anxiety and Depression Scale (HADS-A) [17–19, 21,
22, 24, 26, 28, 29, 33–36], three studies used the Hamilton
Anxiety Scale (HAM-A) [25, 27, 31], one used the Beck
Anxiety Inventory (BAI) [23], two used the DSM-IV criteria
[10, 32], one used the Irritability Depression and Anxiety
scale (IDA) [30], one used the two-item Generalized Anxiety
Disorder questionnaire (GAD-2) [20], two used the Posttrau-
matic Diagnostic Scale (PDS) [9, 37], and one used the PTSD
Checklist Specific for a stressor (PCL-S) [11]. The percentage
of participants deemed to have PSA using these scales ranged
from 6.06% to 56.4%.Themean frequency of PSA symptoms
at baseline was 33.5%.
A range of cut-offs were used in the thirteen studies that
measured anxiety using HADS-A. Seven used a cut-off of ≥8
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Figure 1: Flow diagram showing study selection process.
[21, 22, 26, 29, 33, 35, 36], one study used a cut-off of ≥4 [18],
one study used a cut-off of ≥5 [28], two studies used a score
of 8–10 as possible caseness and a score of ≥11 as probable
caseness [17, 24] and two did not specify a cut-off [19, 34].
Sixteen studies excluded patients withmoderate or severe
cognitive or communication impairment, including aphasia
[9–11, 18, 19, 21–23, 26, 28, 29, 31, 34–37].
The quality of studies is summarised in Supplemental
Table I. According to the STROBE checklist the background
and aims of the majority were clear, and the discussion was
satisfactory, withweaknessesmainly in themethodology: two
out of 24 studies provided sample size calculations; three
explained howmissing data were addressed; six indicated the
number of participants with missing data for each variable
of interest; two described some efforts to address potential
sources of bias; and three out of 11 cohort studies described
how loss to follow-upwas addressed. Ten studies gave sources
of funding.
We were only able to carry out meta-analysis on the
association of PSA with PSD as the other factors did not have
sufficient data.
3.1. Association with Poststroke Depressive Symptoms. Thir-
teen studies (𝑛 = 2408) reported the association between
PSD and PSA. Of which, three studies [21, 32, 36] reported
a significant correlation on multivariate analysis and 10 on
univariate analysis [9–11, 18, 19, 23, 30, 31, 34, 35]. We found
one additional study that did not report the association
but provided enough data for us to calculate an OR from
which we found a significant association (OR = 8.6, 95%
CI 4.46–16.58, 𝑝 ≤ 0.0001) [33]. Another study reported
the association between PSA and depression treatment and
found a significant correlation on univariate analysis at both
3 and 5 years [22].
3.1.1. Overall Meta-Analysis. Of the 13 studies which had
reported the association between PSD and PSA and the
additional study fromwhich we were able to calculate an OR,
13 [9–11, 18, 19, 21, 23, 30, 32–36] provided data for ORs and
thus were included in the meta-analysis. ORs were provided
in four studies [21, 32, 35, 36]; we converted correlation coef-
ficients to ORs in seven [9, 10, 18, 19, 23, 30, 34] and we cal-
culated ORs from raw data in two [11, 33].The summary esti-
mate of OR for this association was 4.66 (95% CI 2.23–9.74,
Figure 2). There was no significant heterogeneity between
studies (𝑄 = 10.67; degree of freedom = 12; 𝑝 = 0.56).
3.1.2. Stratified Meta-Analysis. Three studies reported
adjusted ORs [21, 32, 36] for age, sex, modified Rankin score,
multidimensional scale of perceived social support, Adelaide
activities profile, past depression, and the presence of right
frontal acute infarcts. The remaining 10 studies reported
unadjusted ORs [9–11, 18, 19, 23, 30, 33–35]. This grouping
did not account for a significant part of the heterogeneity
between studies (𝑄 = 0.12; degree of freedom = 1; 𝑝 = 0.73).
The summary OR for the unadjusted studies (𝑛 = 1344;
OR = 5.58; 95% CI 2.33–13.36) was higher (𝑝 ≤ 0.01) than
for the adjusted studies (𝑛 = 1080; OR = 2.52; 95% CI
1.14–5.61).
3.1.3. Publication Bias. The asymmetrical funnel plot
(Figure 3) suggests publication bias. Most published studies
have shown positive association, while few studies reporting
no association have been published.
3.2. Prestroke Anxiety and Prestroke Depression. One study
[32] (𝑛 = 277) reported the association between prestroke
anxiety and PSA and found significant correlation (OR =
2.44, 𝑝 < 0.01). Three studies reported the association
between prestroke depression and PSA; two of these found
a significant correlation (OR = 2.44, 𝑝 < 0.01) [32], (𝛽 =
0.64; 𝑝 = 0.006) [30] and one [21] did not find a significant
correlation (𝑝 = 0.05).
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Figure 2: Random-effects meta-analysis for the association between poststroke anxiety and depressive symptoms. Horizontal axis represents
the odds ratio (OR) comparing the occurrence of depressive symptoms in patients with and without poststroke anxiety. Horizontal error bars
represent the 95% confidence interval (95% CI) of the OR from individual studies. The vertical line represents the summary OR. Symbol size
represents the natural log of the number of participants in that study. ∗The upper limit of the 95% CI beyond 40 does not show in the plot.
3.3. Locus of Control, Coping, and Confidence in Recovery.
One study [34] stated in theirmethods that they would report
theRecovery Locus of Control Scale and “recovery confidence”
as psychological “predictor variables,” but these data were not
reported in the study’s publication. We identified no studies
reporting associations between coping and PSA.
3.4. Fatigue. One study [19] (𝑛 = 98) reported associa-
tions with fatigue and found moderately strong associations
between poststroke fatigue and general anxiety (𝑟 = 0.37, 𝑝 <
0.001), health anxiety (𝑟 = 0.31, 𝑝 < 0.01), and stroke specific
anxiety (𝑟 = 0.37, 𝑝 < 0.001), on univariate analysis. After
hierarchical multiple regression only stroke specific anxiety
remained significantly associated (𝑅2 = 0.32, 𝑝 < 0.001).
3.5. Sleep Disturbance. Two studies (𝑛 = 375) examined the
association with sleep disturbance, both of which found an
association with PSA. One [19] did not specify how sleep
disturbance was measured and the other [32] used the single-
item Likert Scale. We calculated an OR and 95% CI from the
raw data for one (OR = 4.7, 95% CI = 2.26–9.77, 𝑝 ≤ 0.001)
[32] and converted the regression coefficient to an OR for the
other (OR = 4.05, 95% CI = 1.87–8.79, 𝑝 < 0.001) [19].
3.6. Other Psychological Associations. Four studies reported
the association with cognitive impairment. Two studies
[23, 26] found a significant association between cognitive
impairment and PSA; one used The Mini Mental State
Examination (MMSE) score <26 [26] (𝑛 = 178; OR =
0.53; 95% CI = 0.31–0.87; 𝑝 = 0.013); and the other
used the Victoria Stroop dots trial which measures reduced
cognitive speed [23] (𝑛 = 73; 𝑟 = −0.715; 𝑝 < 0.01); the
former excluded patients with “clouding of consciousness”
and moderate-severe aphasia and the latter excluded patients
with aphasia. Two other studies (𝑛 = 2179) [22] and (𝑛 =
277) [32] did not find a significant association with one using
the cut-off MMSE <24 [22] and the other using MMSE as
a continuous variable [32]. However, the former excluded
patients with severe cognitive or communicative impairment.
One study [11] reported an association between PSA and
mental health related quality of life using the 12-itemMedical
Outcomes Short Form Health Survey (SF-12) and found a
significant association (𝑛 = 535; 𝑝 < 0.0001, effect size not
available). One study [10] reported the association between
PSA and trait negativity using The Negative Affect Schedule
and found a significant association on regression analysis
(𝑛 = 102; 𝛽 = 0.28; 𝑝 < 0.01). One study [27] reported
the association between behavioral reactions of denial and
PSA using the Behavioral Index Form which was found to be
significantly associated (𝑛 = 53; 𝑝 = 0.0065; effect size not
available).The variables associated with PSA are summarised
in Supplemental Table II.
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Figure 3: Funnel plot for publication bias. The vertical axis repre-
sents the inverse standard error. The horizontal axis represents the
natural log odds ratio of the associations between poststroke anxiety
and depressive symptoms. The vertical bar represents the summary
estimate of odds ratios.
4. Discussion
Meta-analysis of 13 studies of 2408 patients demonstrated
a statistically significant association between PSA and PSD
(OR = 4.66, 95% CI = 2.23–9.74). Strikingly, there were very
few studies reporting associationwith factors other than PSD.
Very limited data suggested PSA was associated with pre-
stroke anxiety, prestroke depression, fatigue, and sleep. Our
review found no data on the associations between PSA and
locus of control, coping, and confidence. Data on association
between PSA and cognitive impairment were conflicting.
To our knowledge this is the only meta-analysis on the
associations of PSA and psychological factors; although a
systematic review was published previously [7], a meta-
analysis was not performed. In addition to this, our system-
atic review included six further studies with 6577 patients.We
performed a thorough and systematic review using a sensitive
search strategy adapted from a Cochrane review. This review
was based on a protocol written prior to the searches, as
recommended by the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses Protocols (PRISMA-P)
statement [38]. We used a funnel plot to assess publication
bias and the STROBE quality checklist, which is endorsed as
the requirement for reporting observational studies by many
biomedical journals.
Our review has some limitations. Firstly, we could not
include five studies; four of which were published only in
abstract form and the other as a dissertation. We contacted
the authors but received no response. Secondly, in our meta-
analysis of the association with poststroke depressive symp-
toms, only three studies reported ORs that were adjusted for
potential confounding factors; therefore the results from the
10 other studies included may overestimate the associations
found.Whenwe analysed the studieswith adjusted andunad-
justed ORs separately we found the unadjusted group had
a higher summary effect than the adjusted group although
there was no significant heterogeneity between the groups.
There were also limitations of the individual studies: most
did not report sample size calculations or describe efforts to
address potential sources of bias; very few studies provided
reasons for nonparticipation at each stage or explained how
missing data was addressed; most studies were hospital based
and 16 studies excluded patients with significant cognitive
or communication impairment, limiting generalisability and
making it difficult to draw conclusions on the association of
PSA with cognitive impairment.
Our results and another review [4] have found PSA is
common. This high prevalence supports the need to screen
for anxiety in all poststroke patients. There is clear overlap
between symptoms of depression and anxiety after stroke;
this coexistence has been observed in other research [4] and
is demonstrated by our meta-analysis. Thus in patients with
depression one should look for anxiety, and vice versa. Inter-
ventions that target aspects of both anxiety and depression
may also be useful. Antidepressants, for example, selective
serotonin reuptake inhibitors (SSRIs), are used to treat both
depression and anxiety in primary care. A randomised
placebo controlled trial is the only definitive way to evaluate
the effectiveness of antidepressants in poststroke anxiety and
depression. The Fluoxetine or Control Under Supervision
trial (ISRCTN83290762) is an ongoingUK-basedmulticentre
randomised controlled trial of an SSRI in stroke patients.This
is the largest SSRI trial ever undertaken in stroke patients and
is likely to add important data to the effectiveness of pharma-
cological interventions for poststroke anxiety and depression.
The association we found at a single time point does
not allow us to determine the direction of causality. It is
plausible that another factor may cause both depression
and anxiety. Therefore more longitudinal studies exploring
possible direction of causality are required.
Locus of control, coping strategies, and confidence are
potentially modifiable factors that could be targeted for
interventions to treat anxiety after stroke. High levels of
external locus of control have been found to correlate with
higher levels of anxiety in patients with a generalised anxiety
disorder and in patients with multiple sclerosis (MS) and
ovarian cancer [39–42]. Avoidance and emotion-focused
coping styles have been found to correlate with higher levels
of anxiety in patients with MS [43] and specific coping
strategies also correlate with higher levels of anxiety in
patients with chronic obstructive pulmonary disease and
lung cancer [44, 45]. Future studies need to explore the
role of prestroke anxiety and depression, fatigue, sleep, locus
of control, coping, and confidence to help clinicians and
researchers identify those most at risk of developing PSA,
in order to provide potential psychological targets to be
incorporated into a psychological intervention.
5. Conclusions
Significant associations between anxiety and depression after
stroke suggest that PSD should be screened for in patients
with PSA and vice versa. The presence of anxiety or depres-
sion before stroke may be useful in identifying those most
6 Stroke Research and Treatment
at risk of developing PSA. Other potential modifiable factors
that could be targeted in interventions include fatigue and
sleep disturbance. Further research into the association of
PSA with potential treatment targets is required.
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